Results 231 to 240 of about 32,867 (333)

Morin hydrate reduces survival and fertility, delays development and weakens lipid reserves in Aedes aegypti

open access: yesMedical and Veterinary Entomology, Volume 39, Issue 3, Page 592-602, September 2025.
Morin hydrate promoted mortality and reduced the rate of pupation and egg laying in Aedes aegypti larvae that survive treatment. Morin hydrate reduces the levels of triacylglycerol, the main lipid reserve in A. aegypti larvae. The expression of proteins involved in lipogenesis and lipolysis was downregulated and upregulated, respectively, in larvae ...
Luan Valim dos Santos   +9 more
wiley   +1 more source

Rat liver dihydroxyacetone-phosphate acyltransferases and their contribution to glycerolipid synthesis.

open access: hybrid, 1984
Peter Declercq   +5 more
openalex   +1 more source

Plasma lipidomic and metabolomic profiles in high‐grade glioma patients before and after 72‐h presurgery water‐only fasting

open access: yesMolecular Oncology, Volume 19, Issue 8, Page 2249-2269, August 2025.
Presurgery 72‐h fasting in GB patients leads to adaptations of plasma lipids and polar metabolites. Fasting reduces lysophosphatidylcholines and increases free fatty acids, shifts triglycerides toward long‐chain TGs and increases branched‐chain amino acids, alpha aminobutyric acid, and uric acid.
Iris Divé   +7 more
wiley   +1 more source

Roles of Acyl-CoA: Diacylglycerol Acyltransferases 1 and 2 in Triacylglycerol Synthesis and Secretion in Primary Hepatocytes

open access: yesArteriosclerosis, Thrombosis and Vascular Biology, 2015
Chen Li   +6 more
semanticscholar   +1 more source

Subcellular localization of retinoids, retinoid-binding proteins, and acyl-CoA:retinol acyltransferase in rat liver

open access: hybrid, 1987
Earl H. Harrison   +3 more
openalex   +1 more source

Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost

open access: yesClinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 378-385, August 2025.
Model‐informed drug development (MIDD) integrates data to quantify benefit/risk informing objective drug discovery and development decisions. An additional critical benefit of MIDD is postulated to be improvement in trial and program efficiencies. While the application of MIDD has grown, there have been no clear examples across programs to demonstrate ...
Vaishali Sahasrabudhe   +4 more
wiley   +1 more source

Engineering yeast for tailored fatty acid profiles. [PDF]

open access: yesAppl Microbiol Biotechnol
Kobalter S, Wriessnegger T, Pichler H.
europepmc   +1 more source

Lecithin:cholesterol acyltransferase. Functional regions and a structural model of the enzyme.

open access: hybrid, 1987
C.Y. Yang   +6 more
openalex   +1 more source

Home - About - Disclaimer - Privacy